We'll have to agree to disagree there - if you want to track the trajectory of the underlying business, especially when one-off non-cash expenses are being booked, EBIT is the only way to go.
"Competitor snapping at the heels"?? BEACON is a P2 study which only initiated this month so that compound is still 3-4 years away from approval, if it makes it at all.
Ann: Appendix 4E and Annual Report 2022, page-8
-
- There are more pages in this discussion • 19 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.37 |
Change
0.130(0.85%) |
Mkt cap ! $770.0M | |||
| Open | High | Low | Value | Volume |
| $15.36 | $15.54 | $15.18 | $1.274M | 82.63K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 237 | $15.31 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.50 | 282 | 2 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| CUV (ASX) Chart |